InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Appendix 4E and Financial Report to Shareholders 31 Aug 2022 3:03PM $1.560 $0.500 fallen by 67.95%
$7 Response to ASX Aware Query 5 Aug 2022 5:19PM $1.880 $0.500 fallen by 73.40%
$7 June 2022 Quarterly Activities Report 29 Jul 2022 7:51AM $2.010 $0.500 fallen by 75.12%
$7 Appendix 4C Cash Flow Report 29 Jul 2022 7:51AM $2.010 $0.500 fallen by 75.12%
$7 Response to ASX Aware Query 18 Jul 2022 5:39PM $3.290 $0.500 fallen by 84.80%
$7 Response to ASX Price Query 13 Jul 2022 9:33AM $1.980 $0.500 fallen by 74.75%
$7 Zenivol receives formal BfArM approval in Germany 13 Jul 2022 9:33AM $1.980 $0.500 fallen by 74.75%
$7 Trading Halt 12 Jul 2022 3:29PM $1.980 $0.500 fallen by 74.75%
$7 Pause in Trading 12 Jul 2022 2:56PM $1.980 $0.500 fallen by 74.75%
$7 Termination of Scheme Implementation Deed with HHI 22 Jun 2022 9:39AM $1.000 $0.500 fallen by 50%
$7 Trading Halt 20 Jun 2022 10:15AM $1.000 $0.500 fallen by 50%
$7 Pause in Trading 20 Jun 2022 9:54AM $1.000 $0.500 fallen by 50%
$7 EDCDM Technology License Agreement Update 14 Jun 2022 8:02AM $1.000 $0.500 fallen by 50%
$7 Zenivol Longitudinal, RWD Trial in Insomnia Results 8 Jun 2022 8:24AM $1.100 $0.500 fallen by 54.55%
$7 ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial 30 May 2022 8:22AM $1.210 $0.500 fallen by 58.68%
$7 Hope 1 Longitudinal, Real-World Data Trial in ASD Results 17 May 2022 8:22AM $1.175 $0.500 fallen by 57.45%
$7 Final Director's Interest Notice 12 May 2022 4:19PM $1.280 $0.500 fallen by 60.94%
$7 Director Resignation 12 May 2022 4:18PM $1.280 $0.500 fallen by 60.94%
$7 Investor Presentation - Non-deal Roadshow 12 May 2022 9:58AM $1.280 $0.500 fallen by 60.94%
$7 Details of Investor Briefing Session - Update 10 May 2022 11:30AM $1.280 $0.500 fallen by 60.94%
$7 Zelira successfully launches ITURA with CVSCM 9 May 2022 8:23AM $1.280 $0.500 fallen by 60.94%
$7 Details of Investor Briefing Session 9 May 2022 8:22AM $1.280 $0.500 fallen by 60.94%
$7 Appendix 4C Cash Flow Report 29 Apr 2022 8:09AM $2.110 $0.500 fallen by 76.30%
$7 March 2022 Quarterly Activities Report 29 Apr 2022 8:08AM $2.110 $0.500 fallen by 76.30%
$7 Update - Consolidation/Split - ZLD 21 Apr 2022 6:13PM $2.400 $0.500 fallen by 79.17%

151 - 175 of 546 results

Page 7 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.